Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

Ensysce Biosciences, Inc. (ENSC) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

Ensysce Biosciences, Inc. (ENSC), most recent 12 months reported: revenue $4.5M, net loss $12.62M, free cash flow -$7.93M. Latest balance sheet on file: liquid cash $676.7K, total debt $196.84K, net cash $479.86K. From SEC filings. Others in Pharmaceutical Preparations: RANI THERAPEUTICS HOLDINGS, INC. · Bolt Biotherapeutics, Inc. · ENTRADA THERAPEUTICS, INC. · KYNTRA BIO, INC. · CAMP4 Therapeutics Corporation · CHINA PHARMA HOLDINGS, INC. · ProPhase Labs, Inc. · MARKER THERAPEUTICS, INC.

Stock screener

Watchlist